Table 1.
Clinical data of patient in the testing set.
| Characteristics | Patients, n (%) 1 |
|---|---|
| Age at diagnosis, mean ± S.D. 2 (years) | 51.7 ± 9.4 |
| Menopausal status | |
| Premenopausal | 46 (46) |
| Postmenopausal | 55 (55) |
| Missing data | 4 |
| Tumor size (pT) | |
| pTis | 8 (8) |
| pT1 | 50 (48) |
| pT2 | 40 (39) |
| pT3 | 5 (5) |
| pTX | 2 |
| Lymph node metastasis (pN) | |
| Absent (pN0) | 68 (65) |
| Present (pN1–3) | 37 (35) |
| Pathological stage | |
| SI | 46 (44) |
| SII | 47 (45) |
| SIII | 12 (11) |
| Histological type | |
| Invasive ductal carcinoma | 88 (84) |
| Other type | 17 (16) 4 |
| Pathological grade (G) | |
| G1 | 11 (11) |
| G2 | 35 (35) |
| G3 | 54 (54) |
| GX | 5 |
| Estrogen receptor status | |
| Positive | 38 (38) |
| Negative | 61 (62) |
| Missing data | 6 |
| Progesterone receptor status | |
| Positive | 39 (39) |
| Negative | 60 (61) |
| Missing data | 6 |
| Expression of HER2 | |
| Positive | 2 (2) |
| Negative | 97 (97) |
| Missing data | 6 |
| Expression of Ki-67, mean ± S.D. 2 (%) | 32.9 ± 20.3 |
| Molecular subtype | |
| Luminal A | 15 (16) |
| Luminal B | 23 (24) |
| Triple negative | 58 (60) |
| Missing data | 9 |
| Response to neoadjuvant cytotoxic therapy | |
| Complete or partial response | 47 (69) |
| Stable disease or progression | 21 (31) |
| Not applicable 3 | 37 |
Footnotes: 1 Number of patients with % in parentheses; 2 S.D. = standard deviation; 3 patients treated with adjuvant therapy without neoadjuvant cytotoxic therapy; 4 six lobular, six medullary, two metaplastic, one mucinous, one papillary, and one neuroendocrine invasive carcinomas.